Poop pills plus immunotherapy: a new hope for Hard-to-Treat colorectal cancer?
NCT ID NCT04729322
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This small pilot study tests whether giving a fecal microbiota transplant (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help colorectal cancer patients whose tumors did not respond to immunotherapy alone. The trial enrolls 15 adults with metastatic colorectal cancer that is mismatch repair deficient. Participants receive antibiotics, then FMT via colonoscopy or capsules, followed by immunotherapy. The main goal is to see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplant (FMT) plus pembrolizumab or nivolumab
What this could lead to
If successful, this approach could help some colorectal cancer patients who did not respond to immunotherapy alone to have their tumors shrink or stop growing.
What could go wrong
This is a very small pilot trial with only 15 participants, so results may not apply to everyone. The combination of FMT and immunotherapy may cause side effects like infection or immune reactions, and it is not yet proven to work.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.